MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

Начало・Списък с акции・REVOLUTION Medicines Inc

REVOLUTION Medicines Inc

Затворен

СекторЗдравеопазване

49.55 4.16

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

47.4

Максимум

49.77

Ключови измерители
By Trading Economics
Приходи	-34M -248M
Марж на печалбата	-74.379
Служители	700
EBITDA	-24M -261M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+57.58% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	2.2B 9.1B
Предишно отваряне	45.39
Предишно затваряне	49.55

Настроения в новините

By Acuity

50%

166 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

40.67 / 41.96 Подкрепа & съпротива

REVOLUTION Medicines Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.10.2025 г., 23:25 ч. UTC

Значими двигатели на пазара

Salesforce Rises on New FY30 Financial Targets

15.10.2025 г., 18:52 ч. UTC

Печалби

Значими двигатели на пазара

Prologis Shares Gain on Raised Outlook, Data Center Growth

15.10.2025 г., 18:30 ч. UTC

Придобивния, сливания и поглъщания

Constellation Software to Buy U.K.'s Tecvia Holding

15.10.2025 г., 17:19 ч. UTC

Придобивния, сливания и поглъщания

Drahi's Altice Rejects $20 Billion Joint Offer From Peers -- 2nd Update

15.10.2025 г., 17:11 ч. UTC

Придобивния, сливания и поглъщания

Anglo American, MMG Offer Concessions to EU Merger Watchdog in Nickel Deal Probe

15.10.2025 г., 23:48 ч. UTC

Пазарно говорене

Gold Steady, Supported by Expectations of Ongoing Central Bank Purchases -- Market Talk

15.10.2025 г., 23:38 ч. UTC

Пазарно говорене

Nikkei May Rise, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15.10.2025 г., 22:37 ч. UTC

Пазарно говорене

Economic Stars Are Aligning for RBA -- Market Talk

15.10.2025 г., 21:44 ч. UTC

Печалби

Stock Rally Is Lifting Wealth Managers. How Much Is Charles Schwab Benefiting? -- Barrons.com

15.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Financial Services Roundup: Market Talk

15.10.2025 г., 20:44 ч. UTC

Придобивния, сливания и поглъщания

Restaurant Brands Recommends Hldrs Do Not Tender Their Shrs to the Offer >QSR.T

15.10.2025 г., 20:44 ч. UTC

Придобивния, сливания и поглъщания

Restaurant Brands Notified of Unsolicited Mini-Tender Offer to Buy Shrs at $28.80/Shr

15.10.2025 г., 20:43 ч. UTC

Придобивния, сливания и поглъщания

Restaurant Brands Notified of Unsolicited Mini-Tender Offer by NY Stk and Bond LLC to Purchase Up to 10,000 Common Shrs >QSR.T

15.10.2025 г., 20:34 ч. UTC

Печалби

Prologis Raises Outlook as Warehouse Leasing Picks Up -- WSJ

15.10.2025 г., 20:31 ч. UTC

Придобивния, сливания и поглъщания

RBI Recommends Hldrs Reject NYSB's "Mini-Tender Offer"

15.10.2025 г., 20:17 ч. UTC

Придобивния, сливания и поглъщания

GE Vernova Stock Feill With Latest Call to Sell -- Barrons.com

15.10.2025 г., 19:06 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Bank of America, Morgan Stanley, ASML, AMD, Nvidia, Bunge, Progressive, Abbott, and More -- Barrons.com

15.10.2025 г., 19:04 ч. UTC

Пазарно говорене

Oil Futures Post Back-to-Back Losses -- Market Talk

15.10.2025 г., 18:46 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Slip Ahead of Storage Data -- Market Talk

15.10.2025 г., 18:23 ч. UTC

Печалби

This Insurer Is the One of the Worst Stocks in the S&P 500 Today. Here's Why. -- Barrons.com

15.10.2025 г., 17:37 ч. UTC

Придобивния, сливания и поглъщания

Constellation Software's Harris Operating Group Enters Into Agreement To Acquire TECVIA Holding GmbH >CSU.T

15.10.2025 г., 17:34 ч. UTC

Пазарно говорене

Oil Futures Lose Ground on Trade, Oversupply Concerns -- Market Talk

15.10.2025 г., 16:57 ч. UTC

Печалби

The Nation's Biggest Banks Are Saying the Economy Is Still Strong -- WSJ

15.10.2025 г., 16:51 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica Doesn't Disclose Financial Details

15.10.2025 г., 16:50 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica: RetinAI Partners With Pharmaceutical Companies, Research Organizations

15.10.2025 г., 16:49 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica: Deal Reinforces the Group's Med-Tech Journey

15.10.2025 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica: Ikerian Specializes in Artificial Intelligence, Data Management in Eyecare

15.10.2025 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica: Ikerian Is a Health Technology Company, Operating Under the RetinAI Brand

15.10.2025 г., 16:47 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica Buys Ikerian

15.10.2025 г., 16:34 ч. UTC

Пазарно говорене

AMD Data Center Agreements Will Provide Big Revenue Growth -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

REVOLUTION Medicines Inc Прогноза

Ценова цел

By TipRanks

57.58% нагоре

12-месечна прогноза

Среден 74.85 USD 57.58%

Висок 85 USD

Нисък 66 USD

Според 16 анализатори от Wall Street, предложили 12-месечна ценова цел за REVOLUTION Medicines Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

16 ratings

Купи

Задържане

Продай

Според 16 анализатори, дали борсови рейтинги на REVOLUTION Medicines Inc през последните 3 месеца.

Техническа оценка

By Trading Central

40.67 / 41.96Подкрепа & съпротива

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Настроение

By Acuity

166 / 371 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.